SNDL Past Earnings Performance
Past criteria checks 0/6
SNDL has been growing earnings at an average annual rate of 8.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 49.5% per year.
Key information
8.91%
Earnings growth rate
73.76%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 49.52% |
| Return on equity | -9.66% |
| Net Margin | -11.53% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Why Investors Shouldn't Be Surprised By SNDL Inc.'s (NASDAQ:SNDL) Low P/S
May 07
SNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has Increased
May 05
Indiva Integration And 1CM Acquisition Will Expand US Cannabis Footprint
Integration of Indiva and productivity initiatives are projected to enhance margins and profitability, exceeding initial expectations.Analysts Have Made A Financial Statement On SNDL Inc.'s (NASDAQ:SNDL) Third-Quarter Report
Nov 07SNDL Inc.'s (NASDAQ:SNDL) Price Is Right But Growth Is Lacking
Jul 16SNDL: Federal Government Begins Rescheduling Process For Cannabis (Buy)
May 17SNDL Inc. (NASDAQ:SNDL) Shares Fly 60% But Investors Aren't Buying For Growth
Mar 28SNDL Inc.'s (NASDAQ:SNDL) Revenues Are Not Doing Enough For Some Investors
Jan 15SNDL Inc.'s (NASDAQ:SNDL) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jun 22Are Investors Undervaluing SNDL Inc. (NASDAQ:SNDL) By 22%?
Dec 12SNDL Starting To Stand Out Among Canadian Cannabis Players
Aug 05Sundial Growers whipsaws ahead of shareholder meeting on reverse stock split
Jul 20Sundial Growers Looking Bullish As Revenue Growth From Acquisitions Increases
May 19Sundial Growers Doubles Revenue With Spiritleaf Acquisition And Reports Positive EBITDA For Q4-2021
Apr 28Sundial Growers' Cash War Chest And Its Bid To Avoid Another Dilution
Mar 21Sundial Growers Stock: What To Watch For Going Into 2022
Dec 28Taking A Look At The Canadian Cannabis Penny Stock: Sundial Growers
Nov 04Sundial Moves On Alcanna Acquisition And Nova Cannabis Investment
Oct 12Sundial: A Speculative Buy On The Restructure
Sep 25Insight Into Sundial Growers' Q2 2021 Earnings Report
Aug 24Sundial: Can The Recent Acquisition Turn This Story Around?
Jul 23Evaluating Sundial Growers' Acquisition Of Inner Spirit And Partnership With SAF Group
Jul 01Revenue & Expenses Breakdown
How SNDL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 928 | -107 | 219 | 0 |
| 31 Dec 24 | 920 | -95 | 219 | 0 |
| 30 Sep 24 | 911 | -110 | 225 | 0 |
| 30 Jun 24 | 912 | -113 | 224 | 0 |
| 31 Mar 24 | 916 | -136 | 228 | 0 |
| 31 Dec 23 | 909 | -168 | 230 | 0 |
| 30 Sep 23 | 901 | -211 | 221 | 1 |
| 30 Jun 23 | 894 | -287 | 213 | 2 |
| 31 Mar 23 | 886 | -331 | 196 | 2 |
| 31 Dec 22 | 712 | -335 | 158 | 2 |
| 30 Sep 22 | 495 | -266 | 124 | 3 |
| 30 Jun 22 | 278 | -151 | 88 | 2 |
| 31 Mar 22 | 64 | -130 | 60 | 2 |
| 31 Dec 21 | 56 | -227 | 55 | 2 |
| 30 Sep 21 | 47 | -228 | 50 | 2 |
| 30 Jun 21 | 46 | -316 | 49 | 1 |
| 31 Mar 21 | 57 | -296 | 45 | 0 |
| 31 Dec 20 | 61 | -200 | 46 | 0 |
| 30 Sep 20 | 62 | -170 | 59 | 1 |
| 30 Jun 20 | 77 | -184 | 70 | 1 |
| 31 Mar 20 | 76 | -164 | 80 | 3 |
| 31 Dec 19 | 64 | -143 | 86 | 2 |
| 30 Sep 19 | 49 | -156 | 72 | 2 |
| 30 Jun 19 | 21 | -84 | 54 | 2 |
| 31 Mar 19 | 1 | -77 | 37 | 0 |
| 31 Dec 18 | 0 | -68 | 22 | 0 |
| 28 Feb 18 | 0 | -13 | 9 | 0 |
Quality Earnings: SNDL is currently unprofitable.
Growing Profit Margin: SNDL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNDL is unprofitable, but has reduced losses over the past 5 years at a rate of 8.9% per year.
Accelerating Growth: Unable to compare SNDL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.1%).
Return on Equity
High ROE: SNDL has a negative Return on Equity (-9.66%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 02:23 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SNDL Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | ATB Capital Markets |
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Tamy Chen | BMO Capital Markets Equity Research |